and mortality. The objective of this study was to explore whether successful identification of population-specific risk … factors for disease-associated morbidity and mortality may allow for more accurate assessment of the cost effectiveness of …

high rates of morbidity and mortality. The causes of drug-related problems are multifactorial and their assessment has been …, but only one considered costs. Barriers to optimising the economic value of pharmaceutical care were also explored. Common … potential to increase the value of pharmaceuticals in society by minimising drug-related morbidity and mortality. Thus, well …

simulated total management costs for the 4986 patients diagnosed with stage IV NSCLC in Canada in 1992. The other applied US … exclusion of some costs for hospitalisation and/or management of toxicity. Conclusions. Although some limitations apply, the …

supportive care in patients with locally advanced pancreatic carcinoma. Design. The use of resources and associated costs … according to present treatment practice were estimated and calculated retrospectively. Costs were calculated from diagnosis … until death. Actual costs and treatment effects for the patient population were compared with expected treatment costs for …

, laboratory and prescription costs, and morbidity and mortality rates. Main outcome measures and results: The 3 periods had …Objective: To identify any changes in expenditures and in morbidity and mortality with the progression of treatment of … immunosuppression (defined as CD4+ lymphocyte counts <500 cells/mm3). Morbidity and mortality were not changed by the addition of dual …

costs and outcomes in unselected, representative groups of patients. Both direct costs (e.g. costs for medication and … hospitalisation) and indirect costs (e.g. lost productivity costs and reduced quality of life) are important parameters to assess, as … are the costs of chronic adverse effects, research and development costs for new agents, and costs of procedure …

, they are associated with significant adverse effects, the management of which imposes additional costs on the healthcare … treatment costs. This analysis examines data from a published randomised controlled trial of 5 NSAIDs to explore these …; (ii) the management of adverse effects can have a significant impact on costs; and (iii) the additional cost may be …

Heart and Lung Transplantation (ISHLT) overall survival statistics. Incremental costs and incremental cost …-effectiveness ratios were determined using various sources of data, and both costs and consequences were discounted by 3% per year …-years thereafter. Discounted costs per year of life gained were $US1050 (sensitivity analyses $US800 to $US15 400) for simvastatin plus …

mortality is equally significant and has been conservatively estimated at $US30 billion dollars annually, and could exceed $US … mortality has become an increasingly important requirement for reducing healthcare expenditures. This article will review …